A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis
Public ClinicalTrials.gov record NCT00853385. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 3 Randomized, Double-Blind, Active Comparator, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a comparative study of CP 690,550, Humira (adalimumab) and placebo on background methotrexate in patients with Rheumatoid Arthritis. The study is intended to provide evidence of the efficacy and safety of CP 690,550 when dosed 5 mg and 10 mg twice a day on background methotrexate in adult patients with moderate to severe Rheumatoid Arthritis. It is intended to confirm the benefits of CP-690,550 in improving signs and symptoms and physical function that were observed in Rheumatoid Arthritis. An active comparator, adalimumab, is also included.
Study identification
- NCT ID
- NCT00853385
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 717 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2009 (Type not available)
- Primary completion
- Mar 2011 (Actual)
- Completion
- Mar 2011 (Actual)
- Last update posted
- Jan 18, 2013
2009 – 2011
United States locations
- U.S. sites
- 38
- U.S. states
- 19
- U.S. cities
- 36
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Gilbert | Arizona | 85234 | — |
| Pfizer Investigational Site | Glendale | Arizona | 85304 | — |
| Pfizer Investigational Site | Mesa | Arizona | 85202 | — |
| Pfizer Investigational Site | Paradise Valley | Arizona | 85253 | — |
| Pfizer Investigational Site | Phoenix | Arizona | 85037 | — |
| Pfizer Investigational Site | Jonesboro | Arkansas | 72401 | — |
| Pfizer Investigational Site | Fair Oaks | California | 95628 | — |
| Pfizer Investigational Site | San Diego | California | 92108 | — |
| Pfizer Investigational Site | Boulder | Colorado | 80304 | — |
| Pfizer Investigational Site | Largo | Florida | 33777 | — |
| Pfizer Investigational Site | Naples | Florida | 34102 | — |
| Pfizer Investigational Site | Palm Harbor | Florida | 34684 | — |
| Pfizer Investigational Site | Pinellas Park | Florida | 33782 | — |
| Pfizer Investigational Site | Plantation | Florida | 33324 | — |
| Pfizer Investigational Site | St. Petersburg | Florida | 33710 | — |
| Pfizer Investigational Site | Tampa | Florida | 33613 | — |
| Pfizer Investigational Site | Decatur | Georgia | 30033 | — |
| Pfizer Investigational Site | Marietta | Georgia | 30060 | — |
| Pfizer Investigational Site | Rockford | Illinois | 61107 | — |
| Pfizer Investigational Site | Evansville | Indiana | 47714 | — |
| Pfizer Investigational Site | Wichita | Kansas | 67203 | — |
| Pfizer Investigational Site | Lexington | Kentucky | 40504 | — |
| Pfizer Investigational Site | Lexington | Kentucky | 40515 | — |
| Pfizer Investigational Site | Baton Rouge | Louisiana | 70809 | — |
| Pfizer Investigational Site | Haverhill | Massachusetts | 01830 | — |
| Pfizer Investigational Site | Worcester | Massachusetts | 01610 | — |
| Pfizer Investigational Site | Grand Rapids | Michigan | 49546 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45219 | — |
| Pfizer Investigational Site | Oklahoma City | Oklahoma | 73112 | — |
| Pfizer Investigational Site | Greenville | South Carolina | 29601 | — |
| Pfizer Investigational Site | Austin | Texas | 78705 | — |
| Pfizer Investigational Site | Dallas | Texas | 75231 | — |
| Pfizer Investigational Site | Houston | Texas | 77034 | — |
| Pfizer Investigational Site | Lubbock | Texas | 79424 | — |
| Pfizer Investigational Site | Mesquite | Texas | 75150 | — |
| Pfizer Investigational Site | Seattle | Washington | 98104 | — |
| Pfizer Investigational Site | Seattle | Washington | 98122 | — |
| Pfizer Investigational Site | Clarksburg | West Virginia | 26301 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 87 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00853385, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 18, 2013 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00853385 live on ClinicalTrials.gov.